News

Kuros Biosciences reports results for the full year 2020

Schlieren (Zurich), Switzerland, March 18, 2021 – Kuros Biosciences closed the year with outstanding results for 2020, accelerating sales by 58% and initiating the Phase II study for Fibrin PTH, confirming its successful transition into a fully-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration. Kuros raised gross proceeds...

read more

Molecular Partners and Novartis Announce Inclusion of COVID-19 Antiviral Candidate, ensovibep, in NIH-Sponsored ACTIV-3 Trial

Zurich-Schlieren, Switzerland, March 15, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced today announced that ensovibep (formerly MP0420) is expected to be included in a global phase 3...

read more

Molecular Partners to Present Data from Localized Immune Agonist (MP0317), T-cell Engager, and Peptide-MHC Immunotherapy Programs at AACR Annual Meeting

Zurich-Schlieren, Switzerland, March 10, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the upcoming presentation of four posters with data supporting three of the company’s immunotherapy programs at the American Academy for...

read more